To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
There is currently no active drug approved for metastatic chordoma or non-metastatic unresectable chordoma that progresses following radiotherapy. This multicenter, single-arm phase II trial investigated the use of lapatinib, a tyrosine kinase inhibitor, in patients...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
7 Recommendations, most recent by
Past 7 Days
New Articles Recommended
Past 30 Days
174Articles Classified As Controversial8,014 total
77Articles Classified As Novel Drug Target1,671 total
9Articles Classified As Changes Clinical Practice3,958 total
95Articles Classified As Review / Commentary5,611 total
354Articles Classified As Confirmation27,044 total
98Articles Classified As Technical Advance7,031 total
761Articles Classified As New Finding50,384 total
209Articles Classified As Interesting Hypothesis14,429 total
353Articles Classified As Good for Teaching3,429 total
24Articles Classified As Refutation1,608 total
559Articles Classified As Clinical Trial27,520 total
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.